カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の筋強直性ジストロフィー1型（DM1）市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Myotonic Dystrophy Type 1 (DM1) Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19444）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19444
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：101
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の筋強直性ジストロフィー1型（DM1）市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

筋強直性ジストロフィー1型（DM1）市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の筋強直性ジストロフィー1型（DM1）の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

筋強直性ジストロフィー1型（DM1）市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・エクソンディス、エムフラザ、トランスラーナ

用途別セグメントは次のように区分されます。
・病院、診療所、在宅医療

世界の筋強直性ジストロフィー1型（DM1）市場の主要な市場プレーヤーは以下のとおりです。
・Dyne、Audentes、Pfizer、Vertex、PepGen、NeuBase Therapeutics、Lupin、AMO Pharma、Expansion Therapeutics、Harmony Biosciences

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、筋強直性ジストロフィー1型（DM1）製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な筋強直性ジストロフィー1型（DM1）メーカーの企業概要、2019年～2022年までの筋強直性ジストロフィー1型（DM1）の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な筋強直性ジストロフィー1型（DM1）メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別筋強直性ジストロフィー1型（DM1）の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの筋強直性ジストロフィー1型（DM1）の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での筋強直性ジストロフィー1型（DM1）市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および筋強直性ジストロフィー1型（DM1）の産業チェーンを掲載しています。
・第13、14、15章では、筋強直性ジストロフィー1型（DM1）の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 筋強直性ジストロフィー1型（DM1）の概要
- 種類別分析（2017年vs2021年vs2028年）：エクソンディス、エムフラザ、トランスラーナ
- 用途別分析（2017年vs2021年vs2028年）：病院、診療所、在宅医療
- 世界の筋強直性ジストロフィー1型（DM1）市場規模・予測
- 世界の筋強直性ジストロフィー1型（DM1）生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Dyne、Audentes、Pfizer、Vertex、PepGen、NeuBase Therapeutics、Lupin、AMO Pharma、Expansion Therapeutics、Harmony Biosciences
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：エクソンディス、エムフラザ、トランスラーナ
・用途別分析2017年-2028年：病院、診療所、在宅医療
・筋強直性ジストロフィー1型（DM1）の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・筋強直性ジストロフィー1型（DM1）のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・筋強直性ジストロフィー1型（DM1）のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・筋強直性ジストロフィー1型（DM1）の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・筋強直性ジストロフィー1型（DM1）の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Myotonic Dystrophy Type 1 (DM1) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Myotonic Dystrophy Type 1 (DM1) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospitals accounting for % of the Myotonic Dystrophy Type 1 (DM1) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Exondys segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Myotonic Dystrophy Type 1 (DM1) include Dyne, Audentes, Pfizer, Vertex, and PepGen, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Myotonic Dystrophy Type 1 (DM1) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Exondys
Emflaza
Translarna
Market segment by Application can be divided into
Hospitals
Clinics
Home Care
The key market players for global Myotonic Dystrophy Type 1 (DM1) market are listed below:
Dyne
Audentes
Pfizer
Vertex
PepGen
NeuBase Therapeutics
Lupin
AMO Pharma
Expansion Therapeutics
Harmony Biosciences
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Myotonic Dystrophy Type 1 (DM1) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Myotonic Dystrophy Type 1 (DM1), with price, sales, revenue and global market share of Myotonic Dystrophy Type 1 (DM1) from 2019 to 2022.
Chapter 3, the Myotonic Dystrophy Type 1 (DM1) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Myotonic Dystrophy Type 1 (DM1) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Myotonic Dystrophy Type 1 (DM1) market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Myotonic Dystrophy Type 1 (DM1).
Chapter 13, 14, and 15, to describe Myotonic Dystrophy Type 1 (DM1) sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Myotonic Dystrophy Type 1 (DM1) Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Myotonic Dystrophy Type 1 (DM1) Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
1.3 Market Analysis by Application
1.3.1 Overview: Global Myotonic Dystrophy Type 1 (DM1) Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Global Myotonic Dystrophy Type 1 (DM1) Market Size & Forecast
1.4.1 Global Myotonic Dystrophy Type 1 (DM1) Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Myotonic Dystrophy Type 1 (DM1) Sales in Volume (2017-2028)
1.4.3 Global Myotonic Dystrophy Type 1 (DM1) Price (2017-2028)
1.5 Global Myotonic Dystrophy Type 1 (DM1) Production Capacity Analysis
1.5.1 Global Myotonic Dystrophy Type 1 (DM1) Total Production Capacity (2017-2028)
1.5.2 Global Myotonic Dystrophy Type 1 (DM1) Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Myotonic Dystrophy Type 1 (DM1) Market Drivers
1.6.2 Myotonic Dystrophy Type 1 (DM1) Market Restraints
1.6.3 Myotonic Dystrophy Type 1 (DM1) Trends Analysis
2 Manufacturers Profiles
2.1 Dyne
2.1.1 Dyne Details
2.1.2 Dyne Major Business
2.1.3 Dyne Myotonic Dystrophy Type 1 (DM1) Product and Services
2.1.4 Dyne Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Audentes
2.2.1 Audentes Details
2.2.2 Audentes Major Business
2.2.3 Audentes Myotonic Dystrophy Type 1 (DM1) Product and Services
2.2.4 Audentes Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Myotonic Dystrophy Type 1 (DM1) Product and Services
2.3.4 Pfizer Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Vertex
2.4.1 Vertex Details
2.4.2 Vertex Major Business
2.4.3 Vertex Myotonic Dystrophy Type 1 (DM1) Product and Services
2.4.4 Vertex Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 PepGen
2.5.1 PepGen Details
2.5.2 PepGen Major Business
2.5.3 PepGen Myotonic Dystrophy Type 1 (DM1) Product and Services
2.5.4 PepGen Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 NeuBase Therapeutics
2.6.1 NeuBase Therapeutics Details
2.6.2 NeuBase Therapeutics Major Business
2.6.3 NeuBase Therapeutics Myotonic Dystrophy Type 1 (DM1) Product and Services
2.6.4 NeuBase Therapeutics Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Lupin
2.7.1 Lupin Details
2.7.2 Lupin Major Business
2.7.3 Lupin Myotonic Dystrophy Type 1 (DM1) Product and Services
2.7.4 Lupin Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 AMO Pharma
2.8.1 AMO Pharma Details
2.8.2 AMO Pharma Major Business
2.8.3 AMO Pharma Myotonic Dystrophy Type 1 (DM1) Product and Services
2.8.4 AMO Pharma Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Expansion Therapeutics
2.9.1 Expansion Therapeutics Details
2.9.2 Expansion Therapeutics Major Business
2.9.3 Expansion Therapeutics Myotonic Dystrophy Type 1 (DM1) Product and Services
2.9.4 Expansion Therapeutics Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Harmony Biosciences
2.10.1 Harmony Biosciences Details
2.10.2 Harmony Biosciences Major Business
2.10.3 Harmony Biosciences Myotonic Dystrophy Type 1 (DM1) Product and Services
2.10.4 Harmony Biosciences Myotonic Dystrophy Type 1 (DM1) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Myotonic Dystrophy Type 1 (DM1) Breakdown Data by Manufacturer
3.1 Global Myotonic Dystrophy Type 1 (DM1) Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Myotonic Dystrophy Type 1 (DM1) Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Myotonic Dystrophy Type 1 (DM1)
3.4 Market Concentration Rate
3.4.1 Top 3 Myotonic Dystrophy Type 1 (DM1) Manufacturer Market Share in 2021
3.4.2 Top 6 Myotonic Dystrophy Type 1 (DM1) Manufacturer Market Share in 2021
3.5 Global Myotonic Dystrophy Type 1 (DM1) Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Myotonic Dystrophy Type 1 (DM1) Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Myotonic Dystrophy Type 1 (DM1) Market Size by Region
4.1.1 Global Myotonic Dystrophy Type 1 (DM1) Sales in Volume by Region (2017-2028)
4.1.2 Global Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2017-2028)
4.2 North America Myotonic Dystrophy Type 1 (DM1) Revenue (2017-2028)
4.3 Europe Myotonic Dystrophy Type 1 (DM1) Revenue (2017-2028)
4.4 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Revenue (2017-2028)
4.5 South America Myotonic Dystrophy Type 1 (DM1) Revenue (2017-2028)
4.6 Middle East and Africa Myotonic Dystrophy Type 1 (DM1) Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Myotonic Dystrophy Type 1 (DM1) Sales in Volume by Type (2017-2028)
5.2 Global Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2017-2028)
5.3 Global Myotonic Dystrophy Type 1 (DM1) Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Myotonic Dystrophy Type 1 (DM1) Sales in Volume by Application (2017-2028)
6.2 Global Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2017-2028)
6.3 Global Myotonic Dystrophy Type 1 (DM1) Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Myotonic Dystrophy Type 1 (DM1) Sales by Type (2017-2028)
7.2 North America Myotonic Dystrophy Type 1 (DM1) Sales by Application (2017-2028)
7.3 North America Myotonic Dystrophy Type 1 (DM1) Market Size by Country
7.3.1 North America Myotonic Dystrophy Type 1 (DM1) Sales in Volume by Country (2017-2028)
7.3.2 North America Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Myotonic Dystrophy Type 1 (DM1) Sales by Type (2017-2028)
8.2 Europe Myotonic Dystrophy Type 1 (DM1) Sales by Application (2017-2028)
8.3 Europe Myotonic Dystrophy Type 1 (DM1) Market Size by Country
8.3.1 Europe Myotonic Dystrophy Type 1 (DM1) Sales in Volume by Country (2017-2028)
8.3.2 Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Sales by Type (2017-2028)
9.2 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Sales by Application (2017-2028)
9.3 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Market Size by Region
9.3.1 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Myotonic Dystrophy Type 1 (DM1) Sales by Type (2017-2028)
10.2 South America Myotonic Dystrophy Type 1 (DM1) Sales by Application (2017-2028)
10.3 South America Myotonic Dystrophy Type 1 (DM1) Market Size by Country
10.3.1 South America Myotonic Dystrophy Type 1 (DM1) Sales in Volume by Country (2017-2028)
10.3.2 South America Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Sales by Type (2017-2028)
11.2 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Sales by Application (2017-2028)
11.3 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Market Size by Country
11.3.1 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Myotonic Dystrophy Type 1 (DM1) and Key Manufacturers
12.2 Manufacturing Costs Percentage of Myotonic Dystrophy Type 1 (DM1)
12.3 Myotonic Dystrophy Type 1 (DM1) Production Process
12.4 Myotonic Dystrophy Type 1 (DM1) Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Myotonic Dystrophy Type 1 (DM1) Typical Distributors
13.3 Myotonic Dystrophy Type 1 (DM1) Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Dyne Basic Information, Manufacturing Base and Competitors
Table 4. Dyne Major Business
Table 5. Dyne Myotonic Dystrophy Type 1 (DM1) Product and Services
Table 6. Dyne Myotonic Dystrophy Type 1 (DM1) Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Audentes Basic Information, Manufacturing Base and Competitors
Table 8. Audentes Major Business
Table 9. Audentes Myotonic Dystrophy Type 1 (DM1) Product and Services
Table 10. Audentes Myotonic Dystrophy Type 1 (DM1) Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Pfizer Basic Information, Manufacturing Base and Competitors
Table 12. Pfizer Major Business
Table 13. Pfizer Myotonic Dystrophy Type 1 (DM1) Product and Services
Table 14. Pfizer Myotonic Dystrophy Type 1 (DM1) Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Vertex Basic Information, Manufacturing Base and Competitors
Table 16. Vertex Major Business
Table 17. Vertex Myotonic Dystrophy Type 1 (DM1) Product and Services
Table 18. Vertex Myotonic Dystrophy Type 1 (DM1) Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. PepGen Basic Information, Manufacturing Base and Competitors
Table 20. PepGen Major Business
Table 21. PepGen Myotonic Dystrophy Type 1 (DM1) Product and Services
Table 22. PepGen Myotonic Dystrophy Type 1 (DM1) Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. NeuBase Therapeutics Basic Information, Manufacturing Base and Competitors
Table 24. NeuBase Therapeutics Major Business
Table 25. NeuBase Therapeutics Myotonic Dystrophy Type 1 (DM1) Product and Services
Table 26. NeuBase Therapeutics Myotonic Dystrophy Type 1 (DM1) Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Lupin Basic Information, Manufacturing Base and Competitors
Table 28. Lupin Major Business
Table 29. Lupin Myotonic Dystrophy Type 1 (DM1) Product and Services
Table 30. Lupin Myotonic Dystrophy Type 1 (DM1) Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. AMO Pharma Basic Information, Manufacturing Base and Competitors
Table 32. AMO Pharma Major Business
Table 33. AMO Pharma Myotonic Dystrophy Type 1 (DM1) Product and Services
Table 34. AMO Pharma Myotonic Dystrophy Type 1 (DM1) Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Expansion Therapeutics Basic Information, Manufacturing Base and Competitors
Table 36. Expansion Therapeutics Major Business
Table 37. Expansion Therapeutics Myotonic Dystrophy Type 1 (DM1) Product and Services
Table 38. Expansion Therapeutics Myotonic Dystrophy Type 1 (DM1) Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Harmony Biosciences Basic Information, Manufacturing Base and Competitors
Table 40. Harmony Biosciences Major Business
Table 41. Harmony Biosciences Myotonic Dystrophy Type 1 (DM1) Product and Services
Table 42. Harmony Biosciences Myotonic Dystrophy Type 1 (DM1) Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Global Myotonic Dystrophy Type 1 (DM1) Sales by Manufacturer (2019, 2020, 2021, and 2022) & (Units)
Table 44. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 45. Market Position of Manufacturers in Myotonic Dystrophy Type 1 (DM1), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 46. Global Myotonic Dystrophy Type 1 (DM1) Production Capacity by Company, (Units): 2020 VS 2021
Table 47. Head Office and Myotonic Dystrophy Type 1 (DM1) Production Site of Key Manufacturer
Table 48. Myotonic Dystrophy Type 1 (DM1) New Entrant and Capacity Expansion Plans
Table 49. Myotonic Dystrophy Type 1 (DM1) Mergers & Acquisitions in the Past Five Years
Table 50. Global Myotonic Dystrophy Type 1 (DM1) Sales by Region (2017-2022) & (Units)
Table 51. Global Myotonic Dystrophy Type 1 (DM1) Sales by Region (2023-2028) & (Units)
Table 52. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2017-2022) & (USD Million)
Table 53. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2023-2028) & (USD Million)
Table 54. Global Myotonic Dystrophy Type 1 (DM1) Sales by Type (2017-2022) & (Units)
Table 55. Global Myotonic Dystrophy Type 1 (DM1) Sales by Type (2023-2028) & (Units)
Table 56. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2017-2022) & (USD Million)
Table 57. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Type (2023-2028) & (USD Million)
Table 58. Global Myotonic Dystrophy Type 1 (DM1) Price by Type (2017-2022) & (US$/Unit)
Table 59. Global Myotonic Dystrophy Type 1 (DM1) Price by Type (2023-2028) & (US$/Unit)
Table 60. Global Myotonic Dystrophy Type 1 (DM1) Sales by Application (2017-2022) & (Units)
Table 61. Global Myotonic Dystrophy Type 1 (DM1) Sales by Application (2023-2028) & (Units)
Table 62. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2017-2022) & (USD Million)
Table 63. Global Myotonic Dystrophy Type 1 (DM1) Revenue by Application (2023-2028) & (USD Million)
Table 64. Global Myotonic Dystrophy Type 1 (DM1) Price by Application (2017-2022) & (US$/Unit)
Table 65. Global Myotonic Dystrophy Type 1 (DM1) Price by Application (2023-2028) & (US$/Unit)
Table 66. North America Myotonic Dystrophy Type 1 (DM1) Sales by Country (2017-2022) & (Units)
Table 67. North America Myotonic Dystrophy Type 1 (DM1) Sales by Country (2023-2028) & (Units)
Table 68. North America Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2017-2022) & (USD Million)
Table 69. North America Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2023-2028) & (USD Million)
Table 70. North America Myotonic Dystrophy Type 1 (DM1) Sales by Type (2017-2022) & (Units)
Table 71. North America Myotonic Dystrophy Type 1 (DM1) Sales by Type (2023-2028) & (Units)
Table 72. North America Myotonic Dystrophy Type 1 (DM1) Sales by Application (2017-2022) & (Units)
Table 73. North America Myotonic Dystrophy Type 1 (DM1) Sales by Application (2023-2028) & (Units)
Table 74. Europe Myotonic Dystrophy Type 1 (DM1) Sales by Country (2017-2022) & (Units)
Table 75. Europe Myotonic Dystrophy Type 1 (DM1) Sales by Country (2023-2028) & (Units)
Table 76. Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2017-2022) & (USD Million)
Table 77. Europe Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2023-2028) & (USD Million)
Table 78. Europe Myotonic Dystrophy Type 1 (DM1) Sales by Type (2017-2022) & (Units)
Table 79. Europe Myotonic Dystrophy Type 1 (DM1) Sales by Type (2023-2028) & (Units)
Table 80. Europe Myotonic Dystrophy Type 1 (DM1) Sales by Application (2017-2022) & (Units)
Table 81. Europe Myotonic Dystrophy Type 1 (DM1) Sales by Application (2023-2028) & (Units)
Table 82. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Sales by Region (2017-2022) & (Units)
Table 83. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Sales by Region (2023-2028) & (Units)
Table 84. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2017-2022) & (USD Million)
Table 85. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2023-2028) & (USD Million)
Table 86. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Sales by Type (2017-2022) & (Units)
Table 87. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Sales by Type (2023-2028) & (Units)
Table 88. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Sales by Application (2017-2022) & (Units)
Table 89. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Sales by Application (2023-2028) & (Units)
Table 90. South America Myotonic Dystrophy Type 1 (DM1) Sales by Country (2017-2022) & (Units)
Table 91. South America Myotonic Dystrophy Type 1 (DM1) Sales by Country (2023-2028) & (Units)
Table 92. South America Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2017-2022) & (USD Million)
Table 93. South America Myotonic Dystrophy Type 1 (DM1) Revenue by Country (2023-2028) & (USD Million)
Table 94. South America Myotonic Dystrophy Type 1 (DM1) Sales by Type (2017-2022) & (Units)
Table 95. South America Myotonic Dystrophy Type 1 (DM1) Sales by Type (2023-2028) & (Units)
Table 96. South America Myotonic Dystrophy Type 1 (DM1) Sales by Application (2017-2022) & (Units)
Table 97. South America Myotonic Dystrophy Type 1 (DM1) Sales by Application (2023-2028) & (Units)
Table 98. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Sales by Region (2017-2022) & (Units)
Table 99. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Sales by Region (2023-2028) & (Units)
Table 100. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2017-2022) & (USD Million)
Table 101. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Revenue by Region (2023-2028) & (USD Million)
Table 102. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Sales by Type (2017-2022) & (Units)
Table 103. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Sales by Type (2023-2028) & (Units)
Table 104. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Sales by Application (2017-2022) & (Units)
Table 105. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Sales by Application (2023-2028) & (Units)
Table 106. Myotonic Dystrophy Type 1 (DM1) Raw Material
Table 107. Key Manufacturers of Myotonic Dystrophy Type 1 (DM1) Raw Materials
Table 108. Direct Channel Pros & Cons
Table 109. Indirect Channel Pros & Cons
Table 110. Myotonic Dystrophy Type 1 (DM1) Typical Distributors
Table 111. Myotonic Dystrophy Type 1 (DM1) Typical Customers
List of Figures
Figure 1. Myotonic Dystrophy Type 1 (DM1) Picture
Figure 2. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type in 2021
Figure 3. Exondys
Figure 4. Emflaza
Figure 5. Translarna
Figure 6. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application in 2021
Figure 7. Hospitals
Figure 8. Clinics
Figure 9. Home Care
Figure 10. Global Myotonic Dystrophy Type 1 (DM1) Revenue, (USD Million) & (Units): 2017 & 2021 & 2028
Figure 11. Global Myotonic Dystrophy Type 1 (DM1) Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Myotonic Dystrophy Type 1 (DM1) Sales (2017-2028) & (Units)
Figure 13. Global Myotonic Dystrophy Type 1 (DM1) Price (2017-2028) & (US$/Unit)
Figure 14. Global Myotonic Dystrophy Type 1 (DM1) Production Capacity (2017-2028) & (Units)
Figure 15. Global Myotonic Dystrophy Type 1 (DM1) Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Myotonic Dystrophy Type 1 (DM1) Market Drivers
Figure 17. Myotonic Dystrophy Type 1 (DM1) Market Restraints
Figure 18. Myotonic Dystrophy Type 1 (DM1) Market Trends
Figure 19. Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Manufacturer in 2021
Figure 20. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Manufacturer in 2021
Figure 21. Myotonic Dystrophy Type 1 (DM1) Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Myotonic Dystrophy Type 1 (DM1) Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Myotonic Dystrophy Type 1 (DM1) Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Region (2017-2028)
Figure 25. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Region (2017-2028)
Figure 26. North America Myotonic Dystrophy Type 1 (DM1) Revenue (2017-2028) & (USD Million)
Figure 27. Europe Myotonic Dystrophy Type 1 (DM1) Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Revenue (2017-2028) & (USD Million)
Figure 29. South America Myotonic Dystrophy Type 1 (DM1) Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Revenue (2017-2028) & (USD Million)
Figure 31. Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Type (2017-2028)
Figure 32. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Type (2017-2028)
Figure 33. Global Myotonic Dystrophy Type 1 (DM1) Price by Type (2017-2028) & (US$/Unit)
Figure 34. Global Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2017-2028)
Figure 35. Global Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Application (2017-2028)
Figure 36. Global Myotonic Dystrophy Type 1 (DM1) Price by Application (2017-2028) & (US$/Unit)
Figure 37. North America Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Type (2017-2028)
Figure 38. North America Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2017-2028)
Figure 39. North America Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Country (2017-2028)
Figure 40. North America Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Country (2017-2028)
Figure 41. United States Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Type (2017-2028)
Figure 45. Europe Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2017-2028)
Figure 46. Europe Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Country (2017-2028)
Figure 47. Europe Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Country (2017-2028)
Figure 48. Germany Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Region (2017-2028)
Figure 57. China Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Type (2017-2028)
Figure 64. South America Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2017-2028)
Figure 65. South America Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Country (2017-2028)
Figure 66. South America Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Myotonic Dystrophy Type 1 (DM1) Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Myotonic Dystrophy Type 1 (DM1) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Myotonic Dystrophy Type 1 (DM1) in 2021
Figure 78. Manufacturing Process Analysis of Myotonic Dystrophy Type 1 (DM1)
Figure 79. Myotonic Dystrophy Type 1 (DM1) Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の医療用銅管（パイプ）市場2022年：市場規模予測（～2028年）
  • 世界のペースメーカー及び植込み型除細動器（ICD）市場2022年：市場規模予測（～2028年）
  • 世界のアンチトロンビン（組換え）市場2022年：市場規模予測（～2028年）
  • 世界の血栓活性剤（BCA）市場2022年：市場規模予測（～2028年）
  • 世界のマイクロニードル（極細針）市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19444 )"世界の筋強直性ジストロフィー1型（DM1）市場2022年：市場規模予測（～2028年）" (英文：Global Myotonic Dystrophy Type 1 (DM1) Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。